Myocardial Oedema in Acute Myocardial Infarction (AMI)
Despite recent improvements in treatment, myocardial infarction (heart attack) is still a leading cause of illness and death in the UK. Following the acute event, it is difficult to predict which patients are at risk of further problems, such as heart failure and is therefore difficult to know which patients need more aggressive/intensive treatment and monitoring.
There needs to be a test which is safe, reliable and reproducible that can be used shortly after a heart attack to both predict future cardiac events and to allow the efficacy of new treatments to be assessed.
Myocardial oedema (swelling of the heart muscle) has been demonstrated using Cardiac Magnetic Resonance (CMR), to occur following a heart attack and has been suggested as a marker for future cardiac events. The optimum time to perform this scan, the method of data analysis and it's effectiveness as a predictor of future cardiac events has not been adequately assessed.
This trial will assess the amount and natural time-course of oedema in the first 10 days following a heart attack. It will also correlate the amount of oedema with the size of scar (damaged heart muscle) and left ventricular ejection fraction (heart function) at 3 months to assess if it is a predictive marker.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Determination of the Time Course of Myocardial Oedema Post Myocardial Infarction Treated With Primary Angioplasty Using Cardiac Magnetic Resonance Imaging|
- Extent and time course of myocardial oedema over the first 10 days post MI [ Time Frame: Days 1, 3 and 10 post MI ]
- Left ventricular ejection fraction and left ventricular scar size at 3 months [ Time Frame: 90 days post MI ]
|Study Start Date:||November 2009|
|Study Completion Date:||October 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
Post MI patients
Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00987259
|The London Chest Hospital|
|London, Greater London, United Kingdom, E2 9JX|
|Principal Investigator:||Thomas R Burchell, BSc, MB BS||Bart's and The London NHS Trust, United Kingdom|